The impact of immune responses on lung cancer and the development of new treatment modalities.
OBJECTIVE
This presentation covers predominantly review data in relation with immune responses initiating and accompanying lung carcinogenesis or- on the contrary-contributing to novel therapeutic developments. Occasionally, personal findings will be considered. RESULTS 1 OF IMMUNE DEFICIENCY: It is known for several decades that cancer incidence (several sites) is increased in subjects receiving immunosuppressive therapy, e.g. to avoid transplant rejection, or suffering from AIDS. We have observed that in areas heavily polluted by industrial activities, resulting in immune deficiency, cancer incidence is increased, notably for lung cancer. On the other hand, neoplastic cells are able to escape the host's immune responses by inducing apoptosis of the effector T lymphocytes. Apoptosis in T-cells is triggered by the interaction of the membrane receptor Fas with its normal ligand Fas L, or an activating antibody. Now lung carcinoma cells have been shown to express Fas L, enabling them to destroy cytolytic T cells. RESULTS 2 OF IMMUNE TREATMENT: It is well over a century ago that interest in the immunotherapy of cancer was aroused by the observation of tumour regressions concomitant with bacterial infection, an observation leading to the development of 'Coley's toxin', a mixture of killed bacteria (presently known to act through the presence of TNF-alpha). Since these long-standing empirical attempts, a lasting search for immune control of cancer has been initiated, comprising such different approaches as active non-specific immunotherapy, active specific immunotherapy, approaches based on the use of monoclonal antibodies, as well as those depending on cellular immunity and the development of adoptive immunotherapy, and the use of peptide vaccines. These different approaches will be described and their results presented.


CONCLUSIONS
Present state-of-the-art will be discussed and new pathways for development evoked; better understanding of immune mechanisms is opening new avenues for improved treatment efficacy.
Pluygers
E
E
Oncology Department (Honorary), Jolimont Hospital, 159 Rue Ferrer, B-7100, La Louviére, Belgium.
Sadowska
A
A
Chyczewski
L
L
Nikliński
J
J
Niklińska
W
W
Chyczewska
E
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017209:Apoptosis; D002471:Cell Transformation, Neoplastic; D053222:Fas Ligand Protein; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D015994:Incidence; D007694:Killer Cells, Natural; D008175:Lung Neoplasms / Q000276:immunology* / Q000503:physiopathology* / Q000628:therapy*; D008562:Membrane Glycoproteins; D013601:T-Lymphocytes; D022223:Vaccines, Subunit
D000911:Antibodies, Monoclonal; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D022223:Vaccines, Subunit